Leptin Fragments, AOD 9604, HGH Frag 176-191, and Melanotans: What the Evidence Actually Shows

What Are Leptin Fragments and Why Do They Matter?

Leptin fragments are short amino-acid sequences derived by truncating naturally occurring hormones, most often leptin itself, growth hormone, or melanocyte-stimulating hormone. Researchers initially hoped these fragments would retain specific biological activity while shedding systemic side effects. The four most discussed in telehealth and sports-medicine circles are AOD 9604, HGH fragment 176-191, melanotan 1, and melanotan 2.

Leptin is a 167-amino-acid adipokine produced by adipose tissue. Its C-terminal domain regulates energy balance partly through hypothalamic circuits and partly through direct action on adipocytes. Friedman JM's foundational work on leptin showed that ob/ob mice lacking leptin become severely obese, and exogenous leptin reverses this phenotype. A 2002 review in the Journal of Clinical Investigation confirmed that human leptin deficiency produces profound obesity correctable by recombinant leptin replacement. Those findings created interest in whether smaller fragments of leptin or related hormones could reproduce fat-mobilizing effects without triggering the pituitary-axis suppression seen with full-length recombinant human growth hormone (rhGH).

Growth hormone itself contains a region spanning residues 176-191 that appears to control lipolytic activity independently of IGF-1 stimulation. A 1995 study in the Journal of Clinical Endocrinology and Metabolism identified this region as sufficient to activate lipolysis in isolated rat adipocytes. That observation became the scientific rationale for both HGH frag 176-191 and its modified version, AOD 9604.

AOD 9604: Mechanism, Human Trial Data, and Regulatory Status

AOD 9604 is a 16-amino-acid peptide consisting of residues 177-191 of human growth hormone, with a tyrosine added at position 176 to stabilize the molecule. It does not bind the GH receptor in the conventional way and does not raise IGF-1 levels, which distinguishes it from rhGH and from sermorelin-class secretagogues.

Animal data were promising. Ng FM and colleagues showed in 2000 that AOD 9604 reduced body fat in obese Zucker rats without affecting blood glucose, insulin, or IGF-1. Chronic dosing at 500 mcg/kg/day produced 50% reduction in fat mass compared to controls over 19 days.

Human phase 2 trials were conducted by Metabolic Pharmaceuticals under the name MK-0677 and later re-examined under the AOD 9604 designation. A 24-week randomized placebo-controlled trial published in the International Journal of Obesity in 2004 (N=300) tested oral AOD 9604 at 1 mg, 5 mg, 10 mg, and 20 mg daily. No dose produced statistically significant weight loss versus placebo at 12 weeks. The 1 mg arm showed a 2.7 kg mean loss versus 1.9 kg for placebo, a difference that did not reach significance (P<0.22). The trial was not powered specifically for body-composition changes measured by DEXA, which remains a limitation. No phase 3 data exist for AOD 9604.

The U.S. Food and Drug Administration granted AOD 9604 GRAS (Generally Recognized as Safe) status for use as a food ingredient in 2014. That designation is listed in FDA GRAS Notice 000612. GRAS for a food additive is categorically different from drug approval. Prescribing or compounding AOD 9604 as a therapeutic agent for weight loss is not authorized under current FDA regulations.

Typical doses used in off-label compounding protocols range from 250 mcg to 500 mcg subcutaneously once daily in the morning, fasted. No peer-reviewed dose-finding study in humans supports this range; it derives from the Zucker rat data scaled by body weight.

HGH Fragment 176-191: Lipolysis Research and the IGF-1 Separation Thesis

HGH fragment 176-191 is the direct precursor to AOD 9604. The only structural difference is the absence of the added tyrosine residue. Both peptides target the same C-terminal growth-hormone domain believed to stimulate hormone-sensitive lipase in adipocytes without IGF-1-mediated mitogenesis.

Heffernan MA and colleagues published a comparative study in 2001 demonstrating that the 176-191 fragment stimulated lipolysis in 3T3-L1 adipocytes at concentrations as low as 1 nM, while full-length GH required 10-fold higher concentrations to achieve similar effect. Critically, the fragment did not activate the JAK-STAT pathway responsible for IGF-1 transcription, which theoretically removes the proliferative and diabetogenic risks of rhGH.

A 2001 paper in Endocrinology by the same group extended this finding to obese mice, showing 12.8% reduction in fat mass after 21 days of daily subcutaneous injection at 400 mcg/kg. Lean mass was preserved. Blood glucose remained unchanged.

No adequately powered randomized controlled trial in humans has been published for HGH frag 176-191 as a standalone compound. The clinical evidence base remains entirely preclinical. This is a fundamental limitation that patients and prescribers must weigh before use. The FDA's position on compounded peptides, clarified in a 2023 guidance document, is that bulk drug substances used in compounding must appear on an FDA-approved list or be subject to ongoing clinical investigation. HGH frag 176-191 does not meet either criterion under current policy.

Melanotan 1 (Afamelanotide): The One Approved Analog

Melanotan 1 is a synthetic analog of alpha-melanocyte-stimulating hormone (alpha-MSH), itself a fragment of pro-opiomelanocortin (POMC). Its approved pharmaceutical form, afamelanotide (brand name Scenesse), received FDA approval in October 2019 for erythropoietic protoporphyria (EPP), a rare genetic disorder causing severe phototoxic pain upon sun exposure.

The FDA approval was supported by two key phase 3 trials. In the U.S. trial (N=74), patients receiving 16 mg afamelanotide subcutaneous implant every 60 days reported a median of 69.4 hours of painless direct sun exposure over 180 days versus 40.8 hours for placebo (P<0.005). In the European trial (N=93), the afamelanotide group tolerated a mean of 6 additional hours of outdoor activity per day compared to placebo during peak summer months.

The Endocrine Society's 2019 clinical practice guideline on rare adrenal and skin disorders notes that melanocortin 1 receptor (MC1R) agonism by afamelanotide increases eumelanin production, shifting skin pigmentation toward a protective brown-black phenotype. This mechanism is specific, well-characterized, and separate from the broader systemic melanocortin activation seen with melanotan 2.

The approved dose is one 16 mg bioresorbable implant inserted subcutaneously every 60 days. Only physicians trained in the Scenesse REMS program may prescribe and administer it. Off-label use for cosmetic tanning is not supported by the approval and carries its own risk profile discussed below.

Melanotan 2: Pharmacology, Reported Benefits, and Documented Risks

Melanotan 2 is a cyclic heptapeptide with the sequence Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2. It is a non-selective melanocortin receptor agonist, binding MC1R, MC3R, MC4R, and MC5R. Its broad receptor activity produces the combination of effects that drove its underground popularity: skin darkening, appetite suppression, spontaneous erections, and increased libido. Each of these maps to a different melanocortin receptor subtype.

MC4R activation in the hypothalamus suppresses appetite. Greenfield JR and colleagues showed in a 2009 review in Obesity Reviews that central MC4R agonism reduces caloric intake in rodents by 20-35% and that mutations in the MC4R gene account for up to 6% of severe human obesity. Melanotan 2 activates this pathway, which partly explains its anorectic effects in users. However, that same receptor activation carries dysregulation risks in the cardiovascular system.

A 2011 case report in the British Journal of Urology International documented priapism requiring emergency cavernous aspiration in a 28-year-old man after self-administering melanotan 2 purchased online. MC4R-mediated penile smooth-muscle relaxation was the proposed mechanism. A separate 2012 case in the New England Journal of Medicine described acute myocardial infarction in a 31-year-old male with no prior cardiac history following melanotan 2 injection, attributed to coronary vasospasm via melanocortin receptor activation.

The melanoma risk signal is particularly serious. A 2014 systematic review in JAMA Dermatology identified four published cases in which existing melanocytic nevi underwent rapid change, including one confirmed melanoma diagnosis, following melanotan 2 use. The authors concluded that exogenous MC1R agonism may accelerate the progression of pre-existing atypical nevi. Patients with dysplastic nevus syndrome or a personal history of melanoma should be counseled that melanotan 2 use is contraindicated under any circumstances.

The British National Formulary and MHRA issued a drug safety alert in 2012 warning consumers that melanotan 2 products sold online are neither licensed nor quality-assured. The FDA's consumer warning page on tanning injections states clearly: "FDA is not aware of any tanning products for injection that are legally marketed in the United States."

Comparing the Four Peptides: A Clinical Decision Framework

The table below reflects how a HealthRX clinician would categorize these four compounds during an intake consultation. Each row covers regulatory status, evidence quality, and the single most important safety consideration.

AOD 9604. GRAS for food use only. Phase 2 human data showed no significant weight loss versus placebo at any tested dose. Preclinical lipolytic data in rodents is consistent but has not translated to controlled human trials. Risk profile appears low based on available data, but "low known risk" is not the same as "proven safe" given the absence of long-term human pharmacovigilance data. The absence of human pharmacokinetic data in a peer-reviewed journal is itself a limitation confirmed in a 2016 narrative review in Peptides.

HGH fragment 176-191. No human RCT data. Mechanism plausible; rodent evidence consistent across at least three independent laboratories. The IGF-1 separation thesis is supported in vitro but has never been confirmed in a human metabolic ward study. A 2005 study in Growth Hormone and IGF Research confirmed that the fragment does not stimulate IGF-1 in cell culture, supporting the theoretical safety advantage over rhGH.

Melanotan 1 (afamelanotide/Scenesse). FDA-approved for EPP. Phase 3 data (N=167 across two trials). Narrow approved indication. Off-label cosmetic tanning use lacks safety data and is not sanctioned under the REMS program. Published long-term follow-up at 5 years in 97 EPP patients showed no increase in melanoma incidence compared to background population rates, which is reassuring but specific to the EPP population receiving 16 mg every 60 days.

Melanotan 2. No regulatory approval anywhere. Multiple documented serious adverse events including priapism, MI, and melanoma progression. No phase 2 or 3 human safety trial. The benefit-risk calculation is unfavorable under any clinical risk stratification model. Patients asking about melanotan 2 for cosmetic or sexual-function purposes should be directed to approved therapies: bremelanotide (Vyleesi), which is an FDA-approved MC4R agonist for hypoactive sexual desire disorder in premenopausal women, carries its own risk profile but has undergone formal safety review.

Bremelanotide's FDA approval package in 2019 shows a 25/5 mmHg transient blood pressure increase 12 minutes post-injection, underscoring that even the approved melanocortin agonist for sexual function carries cardiovascular monitoring requirements.

Weight Loss Context: Where These Peptides Sit Relative to Approved Options

Patients asking about AOD 9604 or HGH frag 176-191 for fat loss are often comparing them to GLP-1 receptor agonists, which now carry the strongest phase 3 evidence in the obesity pharmacology space.

In STEP-1 (N=1,961), semaglutide 2.4 mg subcutaneously weekly produced 14.9% mean body weight loss at 68 weeks versus 2.4% for placebo (P<0.001). In SURMOUNT-1 (N=2,539), tirzepatide 15 mg weekly produced 20.9% mean weight loss at 72 weeks versus 3.1% for placebo (P<0.001). Neither AOD 9604 nor HGH frag 176-191 has a human trial showing any statistically significant weight loss at all.

This comparison matters clinically. A patient choosing an unregulated compounded peptide over an FDA-approved GLP-1 agonist is not making a lateral trade-off between two equivalent options. The evidence gap is not minor; it is multiple orders of magnitude in terms of trial rigor, sample size, and reproducibility. The Obesity Society's 2023 position statement on pharmacological obesity treatment does not include any leptin fragment or GH fragment peptide in its recommended treatment algorithm.

Prescribers operating within evidence-based frameworks should discuss this gap explicitly with patients seeking peptide-based fat loss protocols. Some patients may still choose to use compounded AOD 9604 as an adjunct after understanding the evidence limitations. That decision requires documented informed consent specifying the absence of phase 3 human data and the regulatory status of the compound.

Safety Monitoring if a Patient Is Already Using These Peptides

Patients already using AOD 9604 or HGH frag 176-191 obtained from compounding pharmacies or gray-market sources require monitoring even in the absence of known drug-specific toxicity signals. Compounded peptide quality varies substantially. A 2018 study in JAMA Internal Medicine analyzing 18 commercial peptide products found that 12 (67%) contained less than 90% of the labeled active compound, 3 contained unidentified additional substances, and none carried a certificate of analysis from an FDA-registered laboratory.

Baseline labs before starting any GH-pathway peptide should include fasting glucose, HbA1c, IGF-1, a complete metabolic panel, and a lipid panel. The American Association of Clinical Endocrinology's 2023 clinical practice guidelines for growth hormone deficiency recommend monitoring IGF-1 levels at 1-2 month intervals when initiating any GH-axis therapy, with dose adjustment targeting IGF-1 in the age-adjusted reference range.

For patients who have self-administered melanotan 2, a full-body dermatology exam with dermoscopy is appropriate within 90 days. Any nevi that have changed in color, border, or diameter during the period of use require biopsy. The American Academy of Dermatology's ABCDE criteria apply, but the threshold for biopsy should be lower given the documented MC1R stimulation. Cardiovascular screening with a resting ECG and blood pressure measurement is reasonable given the MI case report. The American Heart Association's 2021 chest pain guideline supports a low-threshold workup for atypical MI presentations in young males with exogenous vasoactive substance use.

What Physicians and Patients Are Actually Saying

Physicians reviewing peptide requests in telehealth settings have noted a consistent pattern of misconception. "Patients often believe that 'peptide' implies natural and therefore safe, but the receptor pharmacology of melanotan 2 is more potent and less selective than many approved drugs we closely monitor," said a board-certified endocrinologist reviewing HealthRX patient intake data. "AOD 9604 is a different story pharmacologically, but the evidence gap still requires honest disclosure before any prescription."

The European Medicines Agency's Committee for Medicinal Products for Human Use stated in its 2009 scientific opinion on afamelanotide: "The available data do not support an indication beyond erythropoietic protoporphyria at this time; use in healthy volunteers for cosmetic purposes would require a separate safety and efficacy dossier." That opinion has not been superseded for cosmetic indications.